Untreated essential thrombocythemia evolving to biphenotypic leukemia, Philadelphia chromosome positive with monosomy 7: Response to imatinib and reduced-intensity allogeneic stem cell transplant [9]

Leukemia

Volumn 19, Issue 6, 2005, Pages 1095-1096

  Martin, S E ^a,b   Della Valla, J ^b  

^a HELEN F GRAHAM CANCER CENTER   (United States)

^b CHRISTIANA CARE HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ACUTE LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; CASE REPORT; CHROMOSOME TRANSLOCATION; CYTOGENETICS; DRUG RESPONSE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GRAFT VERSUS HOST REACTION; HUMAN; LETTER; MONOSOMY 7; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTHEMIA; ALLOTRANSPLANTATION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MONOSOMY; MULTIMODALITY CANCER THERAPY; MYELOID LEUKEMIA; PATHOPHYSIOLOGY; THROMBOCYTOSIS;

ADULT; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MONOSOMY; PIPERAZINES; PYRIMIDINES; THROMBOCYTOSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 20844439376     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403725     Document Type: Letter

References (8)

1. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34: 29-39.
2. Tefferi A, Fonseca R, Pereira DL, Hoagland HC. A long-term retrospective study of young women with essential thrombocythemia. Mayo Clin Proc 2001; 76: 22-28.
3. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
4. Green A, Campbell P, Buck G, Wheatley K, East C, Bareford D et al. The Medical Research Council PT1 Trial in Essential Thrombocythemia. Blood 2004; 104: 6A.
5. Bolanos-Meade J, Lopez-Arvizu C, Cobos E. Acute myeloid leukaemia arising from a patient with untreated essential thrombocythaemia. Eur J Haematol 2002; 68: 397-399.
6. Sato N, Furukawa T, Masuko M, Hashimoto S, Takahashi H, Baba M et al. Acute promyelocytic leukemia developing in untreated essential thrombocythemia. Am J Hematol 2002; 71: 114-116.
7. Hanks S, Coleman K, Reid S, Plaja A, Firth H, Fitzpatrick D et al. Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B. Nat Genet 2004; 36: 1159-1161.
8. Geller SA, Shapiro E. Acute leukemia as a natural sequel to primary thrombocythemia. Am J Clin Pathol 1982; 77: 353-356.